// App-Quantinova.ai

e16619 : Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact.

Researchers

Presenter

  • Ravi Amrit Madan

Principal Investigators

  • Harpreet Singh

  • Fatima Karzai

  • Marc Robert Theoret

  • Christopher Ryan Heery

  • Julius Strauss

  • Nancy Harold

  • Anna Couvillon

  • Jennifer L. Marte

  • Amy Hankin

  • Italia Grenga

  • Guinevere Chun

  • Lisa M Cordes

  • William Douglas Figg

  • Philip M. Arlen

  • William L. Dahut

  • Jeffrey Schlom

  • James L. Gulley

Medical Centers

  • National Cancer Institute, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • U.S. Food and Drug Administration, Silver Spring, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • Clinical Pharmacology Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01875250

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved